Gamaleya Institute

Covid-19 development round-up: March 25, 2022

The state of the fight: 

Moderna shared new Phase 2/3 data supporting the use of Spikevax in children under age 6.
  Pfizer will supply UNICEF with up to 4 million Paxlovid courses in 2022.
  Boosters of mRNA vaccines continued to offer strong protection against severe Covid-19 outcomes.   AUTHORIZED VACCINES

 
Moderna claimed clinical trial success for its vaccine in children ages 6 months to under 6 years. An interim analysis of Phase 2/3 results showed a “…

Mentions:
Covid-19, vaccines, drugs, Moderna, BBIL, CanSino, CNBG, Sinopharm, Novavax, Sinovac, J&J, Gamaleya Institute, SII, WHO, Pfizer, BioNTech, SK Bioscience, Biovac, AstraZeneca, MPP, GSK, Vir, Gilead, Merck
Read more
Covid-19 development round-up: March 18, 2022

The state of the fight: 

Medicines Patent Pool sublicensed Pfizer’s Paxlovid to 35 generics manufacturers.
  Key WTO members reached a tentative agreement to waive some IP rights on Covid-19 vaccines.
  Moderna and Pfizer asked the U.S. FDA to authorize fourth doses of their respective jabs.   AUTHORIZED VACCINES

 
Medigen’s protein subunit vaccine (MVC-COV1901) offered similar safety and immunogenicity for adolescents as it did for adults, the Taipei-based…

Mentions:
Covid-19, vaccines, drugs, Medigen, WHO, Moderna, Sinovac, AstraZeneca, FDA, Pfizer, BioNTech, CanSino, Anhui Longcom, Clover, SII, CureVac, GSK, WTO, COVAX, Gamaleya Institute, Gavi, Bio E, J&J, MPP, DNDi, Vir, Merck, Shionogi
Read more
Covid-19 development round-up: March 10, 2022

The state of the fight: 

Moderna pledged permanently to forgo enforcement of its Covid-19 vaccine patents for shots made “in or for” 92 LMICs.
  Aspen Pharmacare will market an Aspen-branded version of J&J’s vaccine in Africa.
  Fluvoxamine reduced the risk of Covid-19 hospitalization and clinical deterioration by 31% in a meta-analysis.   BOOSTERS

 
A WHO technical advisory group now “strongly supports urgent and broad access” to Covid-19 booster doses…

Mentions:
Covid-19, vaccines, drugs, WHO, SII, Novavax, Bharat Biotech, Gamaleya Institute, Moderna, Pfizer, BioNTech, Butantan Institute, COVAX, CEPI, CNBG, Sinopharm, Sinovac, NIAID, Africa CDC
Read more
Covid-19 development round-up: March 4, 2022

The state of the fight: 

Pfizer/BioNTech’s Comirnaty appeared to offer only 12% effectiveness against Omicron in children ages 5-11.
  South Africa’s Biovac partnered with nine development institutions to boost local vaccine manufacturing capacity.
  Eli Lilly’s arthritis drug Olumiant reduced the risk of death by 13% in hospitalized Covid-19 patients.   AUTHORIZED VACCINES

 
Pfizer/BioNTech’s Comirnaty is far less protective against infection in children ages…

Mentions:
Covid-19, vaccines, drugs, Pfizer, BioNTech, Novavax, Sinovac, Valneva, FDA, Bharat Biotech, Inovio, Shionogi, CureVac, GSK, Biovac, Gamaleya Institute, WHO, MPP, Moderna, Bio Farma, ACT-A, EMA, J&J, AstraZeneca, Merck, Regeneron, Roche, Lilly, Gilead, DNDi
Read more
Covid-19 development round-up: February 25, 2022

The state of the fight: 

Sanofi and GSK’s vaccine candidate demonstrated 58% efficacy against symptomatic Covid-19 in Phase 3.
  Hetero Pharma’s generic version of Merck’s molnupiravir reduced the risk of hospitalization by over 65%.
  Britain and Japan pledged a combined $514 million to CEPI’s pandemic preparedness plan.   AUTHORIZED VACCINES

 
The U.S. FDA lifted its clinical hold on Bharat Biotech’s Covaxin, clearing the way for the inactivated vaccine to…

Mentions:
Covid-19, vaccines, drugs, Bharat Biotech, FDA, Ocugen, Pfizer, BioNTech, CDC, Medicago, GSK, Moderna, Gamaleya Institute, CNBG, Sinopharm, EMA, CanSino, Anhui Zhifei Longcom, Sanofi, Thermo Fisher, Valneva, CEPI, AstraZeneca, Sinovac, Africa CDC, COVAX, WHO, J&J, Vir, Merck, Gilead, Shionogi, Suzhou Abogen, Walvax
Read more
Covid-19 development round-up: February 18, 2022

The state of the fight: 

Moderna applied for South African patents on its vaccine, potentially jeopardizing the work of the WHO-led mRNA vaccine “hub” operating in the country.
  WHO named five additional African countries that will receive vaccine technology from the hub.
  Laboratorios Farmacéuticos Rovi inked a 10-year mRNA vaccine manufacturing extension with Moderna.   AUTHORIZED VACCINES

                                       
Medigen’s protein subunit…

Mentions:
Covid-19, vaccines, drugs, Medigen, AstraZeneca, Biological E, Moderna, Novavax, Abogen, Walvax, Gamaleya Institute, WHO, Afrigen, Pfizer, BioNTech, COVAX, Gavi, Merck, Gilead, Roche, Shionogi
Read more
Covid-19 development round-up: February 11, 2022

The state of the fight: 

A Lilly mAb active against Omicron won a U.S. FDA emergency use nod.
  Novavax’s shot proved 80% efficacious in adolescents ages 12-17, according to a Phase 3 readout.
  Vaxxinity’s UB-612 vaccine candidate performed better against Omicron than an mRNA-based comparator jab.

 

AUTHORIZED VACCINES

 
J&J’s single-dose shot was only 53% efficacious against moderate to severe Covid-19 (28 days post-injection) in a final analysis…

Mentions:
Covid-19, vaccines, drugs, J&J, Novavax, FDA, Pfizer, BioNTech, Bharat Biotech, CNBG, Sinopharm, Gamaleya Institute, Sinovac, EMA, AstraZeneca, Walvax, Moderna, Biological E, African Union, COVAX, WHO, ACT-A, Lilly, Gilead, Merck, GSK, Vir, Regeneron, Roche, DNDi, Novartis
Read more
Covid-19 development round-up: February 4, 2022

The state of the fight: 

South Africa’s Afrigen has produced the first batch of its version of Moderna’s mRNA-based vaccine.
  Afrigen also secured a $45 million grant from the U.N.-backed Medicines Patent Pool.
  Moderna’s Spikevax notched full approval in the U.S.

REGULATORY UPDATES

 
Pfizer and BioNTech have begun rolling data submission for authorization of their Comirnaty shot in children between ages 6 months and 5 years “at the request” of the U.S…

Mentions:
Covid-19, vaccines, drugs, NIH, Moderna, FDA, CDC, Pfizer, BioNTech, Gamaleya Institute, Novavax, J&J, Sinovac, CNBG, Sinopharm, EuBiologics, WHO, Afrigen, Biovac, BioManguinhos, MPP, Zydus Cadila, Merck, Shionogi
Read more
Covid-19 development round-up: January 21, 2022

The state of the fight: 

African vaccine production advanced on multiple fronts, including the opening of a new manufacturing plant in South Africa.
  The COVAX AMC seeks an additional $5.2 billion this year.
  Merck will supply UNICEF with up to 3 million courses of molnupiravir in the first half of 2022.

AUTHORIZED VACCINES  

The Chilean health ministry released data on the Sinovac jab’s effectiveness in children. In kids ages 6-11, the topline numbers…

Mentions:
Covid-19, vaccines, drugs, WHO, Pfizer, BioNTech, Sinovac, EMA, Moderna, J&J, SII, BBIL, Novavax, Gamaleya Institute, Valneva, Clover, CEPI, IPD, COVAX, Gavi, Merck, UNICEF, MPP, GSK, Vir, Gilead, Regeneron, Roche
Read more
Covid-19 development round-up: January 7, 2022

The state of the fight: 

India granted Biological E’s Corbevax—a low-cost, patent-free vaccine—its first regulatory authorization.
  A J&J booster was 85% effective against hospitalization in South Africa during the Omicron wave.
  India authorized molnupiravir but omitted the antiviral from its recommended clinical protocol on safety concerns.

 

AUTHORIZED VACCINES

 
Bharat Biotech’s Covaxin generated “superior antibody responses” in children…

Mentions:
Covid-19, vaccines, drugs, BBIL, Pfizer, BioNTech, AstraZeneca, J&J, Janssen, CanSino, CDC, Bio E, Novavax, FDA, SII, CNBG, Sinopharm, Moderna, Gamaleya Institute, Sinovac, SK Bioscience, CEPI, GSK, Vir, Merck, Regeneron, Roche, Gilead, Shionogi
Read more
Subscribe to Gamaleya Institute